Featured Research

from universities, journals, and other organizations

Drug-embedded Microparticles Bolster Heart Function In Animal Studies

Date:
October 21, 2008
Source:
Emory University
Summary:
Tiny polymer beads embedded with anti-inflammatory drugs can reduce damage to the heart when injected into rats' hearts after a simulated heart attack. The beads (average size: 1/50 of a millimeter wide) are made of a "polyketal" material that breaks down over a few weeks in the body. Because polyketals are less inherently inflammatory than other biodegradable polymers, they could be used to treat several inflammatory diseases.

Researchers at Emory University and Georgia Institute of Technology have developed tiny polymer beads that can slowly release anti-inflammatory drugs and break down into non-toxic components.

Related Articles


When injected into rats' hearts after a simulated heart attack, the drug-embedded "microparticles" reduce inflammation and scarring, the researchers found. Injecting the particles could cut the area of scar tissue formed after the heart attack in half and boost the ability of the heart to pump blood by 10 percent weeks later.

Doctors believe that certain anti-inflammatory drugs, if delivered directly into the heart after a heart attack, could prevent permanent damage and reduce the probability of heart failure later in life.

Fulfilling this idea -- getting drugs to the right place at the right time -- is more challenging than simply swallowing an aspirin, says senior author Michael Davis, PhD, assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.

"If you look at previous studies to see what it would take to get enough of these drugs into the heart, they did things like direct injections twice a day," he says. "And there are clear toxicity issues if the whole body is exposed to the drug."

As an alternative, Davis and graduate student Jay Sy, the first author of the paper, turned to microscopic particles made of a material called polyketals, developed by co-author Niren Murthy, PhD, assistant professor of biomedical engineering.

The microparticles break down over a few weeks in the body, releasing the experimental drug SB239063. This drug inhibits an enzyme, MAP kinase, which is important during the damaging inflammation that occurs after a heart attack.

Davis says the drug gradually leaches out of the polyketal particles – half is gone after a week of just sitting around in warm water. In addition, the microparticles are broken down by white blood cells called macrophages.

"These are actually cells we're trying to reach with the drug, because they're involved in the inflammatory response in the heart," he says. "The macrophages can surround and eat the particles, or fuse together if the particles are too big."

Davis says polyketals have an advantage over other biodegradable polymers, in that they break down into neutral, excretable compounds that aren't themselves inflammatory.

Polyesters such as PLGA (polylactic-co-glycolic acid) are approved for use in sutures and grafts. However, when they are made into particles small enough to be broken down in the body, polyesters cause inflammation – exactly what the drugs are supposed to stop, he says.

When the particles were injected into rats' hearts, the researchers could see an inhibition of the MAP kinase enzyme lasting for a week. However, the effect on heart function was greater after 21 days. Davis says this result suggests that the main way the particles helped the heart was to prevent the scarring that sets in after the initial tissue damage of a heart attack.

He and Murthy are exploring polyketal particles as delivery vehicles for drugs or proteins in several organs: heart, liver, lungs and spinal cord.

The research was funded by EmTech Bio, the National Science Foundation, the National Institutes of Health, the Department of Homeland Security and a seed grant from Johnson & Johnson.


Story Source:

The above story is based on materials provided by Emory University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sy, J.C. et al. Sustained release of a p38-inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction. Nature Materials, Vol, p, Oct /Nov 2008

Cite This Page:

Emory University. "Drug-embedded Microparticles Bolster Heart Function In Animal Studies." ScienceDaily. ScienceDaily, 21 October 2008. <www.sciencedaily.com/releases/2008/10/081019144629.htm>.
Emory University. (2008, October 21). Drug-embedded Microparticles Bolster Heart Function In Animal Studies. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2008/10/081019144629.htm
Emory University. "Drug-embedded Microparticles Bolster Heart Function In Animal Studies." ScienceDaily. www.sciencedaily.com/releases/2008/10/081019144629.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) — Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) — AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) — Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins